By Megan Tooley and Brian Contos, Cardiovascular Roundtable
For CV programs considering developing a transcatheter aortic valve replacement (TAVR) program, the anticipated "halo effect" of TAVR on the business as a whole is understandably a significant driver. This halo effect is typically the result of downstream volumes from valve screening clinics (e.g., patients deemed ineligible for TAVR receiving another procedure), upstream and downstream diagnostics required for TAVR, and new referral relationships established due to the presence of this high-end procedure and enhanced reputation.
But how substantial is this halo effect on a TAVR program’s overall valve volumes? We ran the numbers to find out.
Next, Check Out
Cardiovascular Clinical Technology Compendium